首页> 外文期刊>Expert opinion on biological therapy >Engineering cell platforms for myocardial regeneration.
【24h】

Engineering cell platforms for myocardial regeneration.

机译:用于心肌再生的工程细胞平台。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Various engineered 'cell-platforms' have been reported in recent years for the possible treatment of myocardial infarction (MI) and end-stage heart failure. These engineered platforms rely on two key factors: cells and/or biomaterial scaffolds for the regeneration of the infarcted heart tissue. AREAS COVERED: Two major cell-platform approaches are described and broadly categorized as 'injectable cell platforms' and 'patch-based cell platforms'. The recent advancements in these cell-platforms in terms of their relative successes in-vivo as well as their clinical feasibility are summarized. Natural as well as synthetic scaffolds, with or without the cellular component, are compared with cell based therapy alone. This review focuses on achievements, as well as the gaps that are presently checking any progress towards producing clinically relevant panacea for myocardial regeneration. EXPERT OPINION: Cardiac and induced pluripotent stem cells will probably be the focus of future research. The combined cell-biomaterial scaffold therapy is superior to cell therapy alone. Nevertheless, encouraging pre-clinical successes have limited translation into clinical practice due to limited cell survival post transplantation, inadequate construct thicknesses for human-sized hearts and the traditional use of 'flat (2D) tissue culture' techniques. The development of complementary dynamic 3D cultivation platforms will probably lead to improved outcomes and enable fast screening of various therapeutic approaches.
机译:简介:近年来,已报道了多种工程化的“细胞平台”,可用于治疗心肌梗塞(MI)和终末期心力衰竭。这些工程平台依赖两个关键因素:用于梗塞心脏组织再生的细胞和/或生物材料支架。涵盖的领域:描述了两种主要的细胞平台方法,并将其大致分为“可注射细胞平台”和“基于补丁的细胞平台”。总结了这些细胞平台在体内的相对成功及其临床可行性方面的最新进展。将具有或不具有细胞成分的天然支架和合成支架与仅基于细胞的疗法进行比较。这篇综述的重点是成就,以及目前正在检查在生产临床上相关的灵丹妙药用于心肌再生方面的进展的差距。专家意见:心脏和诱导性多能干细胞可能会成为未来研究的重点。组合的细胞生物材料支架疗法优于单独的细胞疗法。然而,由于移植后细胞的存活率有限,用于人大小心脏的构建体厚度不足以及传统使用的“平面(2D)组织培养”技术,令人鼓舞的临床前成功成果已被限制在临床实践中。互补动态3D培养平台的开发可能会导致改善结果,并能够快速筛选各种治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号